Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;98(1):E15-E19.
doi: 10.1002/ajh.26602. Epub 2022 Jun 4.

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

Meletios A Dimopoulos  1 , Philippe Moreau  2 , Bradley Augustson  3 , Nelson Castro  4 , Tomas Pika  5 , Sosana Delimpasi  6 , Javier De la Rubia  7 , Angelo Maiolino  8 , Tony Reiman  9 , Joaquin Martinez-Lopez  10 , Thomas Martin  11 , Joseph Mikhael  12 , Kwee Yong  13 , Marie-Laure Risse  14 , Gaelle Asset  15 , Sylvia Marion  16 , Roman Hajek  17   18
Affiliations

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

Meletios A Dimopoulos et al. Am J Hematol. 2023 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Roman Hajek: Consulting or Advisory role—Takeda, Amgen, Celgene, Abbvie, Bristol‐Myers Squibb, PharmaMar, Janssen‐Cilag, Novartis; Speakers' Bureau—Takeda, Amgen; research funding—Novartis, Bristol‐Myers Squibb, Amgen, Celgene, Takeda. Philippe Moreau: Consulting or Advisory role—Celgene, Janssen, Amgen, GlaxoSmithKline, Sanofi, Abbvie; Honoraria—Celgene, Janssen‐Cilag, Amgen, GlaxoSmithKline, Sanofi, Abbvie. Sosana Delimpasi: Consulting or Advisor role—Janssen, Takeda, Amgen; Speakers' Bureau—Janssen, Takeda, Amgen. Javier De la Rubia: Speakers' Bureau—Amgen, Bristol‐Myers Squibb; Honoraria—Amgen, Celgene, Takeda, Janssen, Sanofi, Bristol‐Myers Squibb. Tony Reiman: Research funding—Sanofi, Terry Fox Research Institute, Canadian Cancer Society, New Brunswick Health Research Foundation, New Brunswick Foundation for Innovation, Canadian Institutes of Health Research; Hematology Disease Site Co‐Chair–Canadian Cancer Trials Group. Joaquin Martinez‐Lopez: Honoraria—Sanofi, Janssen, Novartis, Bristol‐Myers Squibb, Incyte, Roche; research funding—Janssen, Novartis, Bristol‐Myers Squibb, Incyte, Roche; nonfinancial support—Janssen, Novartis, Bristol‐Myers Squibb. Thomas Martin: Consulting or advisory role—Juno Therapeutics, GlaxoSmithKline; research funding—Sanofi, Amgen, Janssen. Joseph Mikhael: Honoraria—Amgen, Karyopharm Therapeutics, Sanofi, Janssen, Celgene, GlaxoSmithKline, Takeda. Marie‐Laure Risse, Gaelle Asset, and Sylvia Marion are employed by Sanofi and may have stock and/or stock options in the company. Meletios A. Dimopoulos: Consulting or advisory role—Amgen, Janssen‐Cilag, Takeda, Bristol‐Myers Squibb, Beigene; honoraria—Amgen, Takeda, Janssen‐Cilag, Bristol‐Myers Squibb, Beigene.

Figures

FIGURE 1
FIGURE 1
Efficacy with Isa‐Kd versus Kd. (A) PFS by number of prior lines of therapy and refractory status; depth of response by (B) number of prior lines of therapy, (C) lenalidomide‐refractory status, or (D) bortezomib‐refractory status. Bor, bortezomib; CI, confidence interval; CR, complete response; d, dexamethasone; IMiD, immunomodulatory drug; Isa, isatuximab; K, carfilzomib; Len, lenalidomide; mPFS, median progression‐free survival; MRD−, minimal residual disease negativity; NC, not calculated; ORR, overall response rate; PFS, progression‐free survival; PI, proteasome inhibitor; VGPR, very good partial response
See this image and copyright information in PMC

References

    1. Raab MS, Fink L, Schoen P, et al. Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016. Br J Haematol. 2019;185(5):981‐984. - PubMed
    1. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low‐dose dexamethasone versus pomalidomide and low‐dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA‐MM): a randomised, multicentre, open‐label, phase 3 study. Lancet. 2019;394(10214):2096‐2107. - PubMed
    1. Moreau P, Dimopoulos M, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open‐label, randomised phase 3 trial. Lancet. 2021;397(10292):2361‐2371. - PubMed
    1. Moreau P, Joshua D, Chng WJ, et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017;31(1):115‐122. - PMC - PubMed
    1. Quach H, Nooka A, Samoylova O, et al. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. Br J Haematol. 2021;194(4):784‐788. - PubMed

Publication types

MeSH terms